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乳腺癌进展和转移中起重要作用，其在 TNBC 细胞和组织中过表达，可能是 TNBC
诊断和治疗的潜在分子靶点。 
本研究以 ICAM-1 为研究对象，围绕如何针对 TNBC 中 ICAM-1 的活体无创检
测，开展对 ICAM-1 具有靶向性的单克隆抗体放射性标记及生物评价研究。旨在





表达阳性，其阳性率显著高于 non-TNBC细胞 （BT474和 MCF-7）（P < 0.05）比
non-TNBC细胞高出 6-11倍。MDA-MB-231和 MCF-7移植瘤组织免疫化学染色鉴定
结果与细胞流式结果一致。 
在第三章中，我们对抗 ICAM-1 抗体进行了 131I 标记研究，成功制备稳定的
131I-aICAM1探针，并对探针进行了一系列评价。131I-aICAM1的标记率 > 90 %，
放射化学纯度 > 99 %，探针置于 PBS和胎牛血清于室温条件下，放置 2 d 后放
射化学纯度 > 80 %，说明该标记物的体外稳定性较好。通过细胞饱和实验、细
胞免疫荧光和组织放射自显影等手段对探针进行鉴定。该探针具有良好的免疫活
性和特异性，能够和 MDA-MB-231细胞上 ICAM-1特异性结合且具有较高的亲和力
















在第四章中，我们对 125I-aICAM1 进行了体内 SPECT 显像研究。当抗体蛋白
注射剂量为 10 μg 时，125I-aICAM1的体内 SPECT 显像效果最好。125I-aICAM1可
以特异且有效地富集至 MDA-MB-231 移植瘤，显示出良好的肿瘤靶向性，其在正
常器官快速清除并具有高的靶/非靶比值，在注射后 48 h时，肿瘤清晰可见，随
着时间的推移，肿瘤积累量增加。在注射后 1、24、48、72和 96 h 时，肿瘤部
位的摄取分别为 3.09 ± 0.09 %ID/g、7.02 ± 0.99 %ID/g、8.87 ± 0.92 %ID/g、
11.79 ± 2.15 %ID/g 和 15.10 ± 1.40 %ID/g。96 h 时肿瘤部位的摄取效果
最佳，此时肿瘤/心脏、肿瘤/肝脏和肿瘤/肌肉比值分别为 3.66 ± 0.34、5.36 




125I-aICAM1 是使用 SPECT 检测体内 ICAM-1 表达的新型的强有力的示踪剂，
该探针有望对乳腺癌的分子分型研究提供信息，进行三阴性乳腺癌非侵入性
SPECT成像并同步指导 131I-aICAM1放射免疫治疗。 



















Cancer has become the biggest cause of death in the world. Breast cancer, one of 
the most common cancer in women, occurs in the epithelial tissues. Millions of women 
around the world are suffering from breast cancer. Comprehensive molecular analysis 
of breast cancer shows that breast cancer is a collection of molecularly distinct 
neoplastic diseases of the breast. Breast cancers are heterogeneous, both in their 
pathology and in their molecular profiles. Different molecular subtypes of breast cancer, 
its clinical manifestations, prognosis and treatment are different. Triple negative breast 
cancer (TNBC) is a molecularly heterogeneous disease, characterized by a low 
expression of the estrogen receptor (ER), progesterone receptor (PR), and human 
epidermal growth factor receptor 2 (HER-2). The significant growth and metastasis of 
TNBC tumors, coupled with fewer treatment options and a lack of recognized 
molecular targets for therapy, have resulted in relatively poorer outcome and higher 
mortality rates for patients with TNBC relative to those with other breast cancer 
subtypes. ICAM-1 plays an important role in breast cancer progression and metastasis. 
ICAM-1 overexpressed in human triple negative breast cancer (TNBC) cell lines and 
tissues is a potential molecular target and biomarker for TNBC therapy and diagnosis. 
The aim of this study was to prepare a novel TNBC-targeted probe. Physical and 
chemical properties of probe were determined and a series of biological evaluation in 
vivo and in vitro were also done to examine the prospects of TNBC diagnosis and 
treatment. 
In the second chapter, breast cancer cells ICAM-1 surface protein expression was 
evaluated by flow cytometry. The results showed that ICAM-1 was negative expression 
on non-TNBC cells (BT474 and MCF-7), the positive rates of TNBC cells (MDA-MB-
231 and MDA-MB-453) were significantly higher than non-TNBC cells (BT474 and 
MCF-7) (Fig. 1). TNBC cells exhibited about 6 to 11-fold higher ICAM-1 surface 
protein levels than non-TNBC cells. Immunohistochemical staining of MDA-MB-231 
and MCF-7 xenografts was consistent with the flow cytometry result. 
In the third chapter, we investigate the radioiodination labeling method of anti-
ICAM-1 antibody, and successfully prepared the stable 131I-aICAM1 probe. A series of 
evaluation of the probe were determined. 131I-aICAM1 radiolabeling yield > 90%, 
radiochemical purity > 99%. In vitro stability of 131I-aICAM1 in PBS and fetal bovine 
















indicating the 131I-aICAM1 had a good stability in vitro. Cell saturation experiments, 
cellular immunofluorescence and tissue autoradiography were used to evaluate the 
probe. The probe has good immunological activity and specificity, and can specifically 
bind to ICAM-1 on MDA-MB-231 cells with high affinity (Kd = 2.71 ± 0.20 nM). 
In the fourth chapter, the dose-escalation study showed that 125I-aICAM1 
efficiently targeted MDA-MB-231 xenografts at antibody protein doses up to 10 μg.  
From the results of SPECT imaging study, MDA-MB-231 tumor could be visualized 
clearly using 125I-aICAM1 at 48 h after injection, and the tumor accumulation increased 
over time with the uptake of 3.09 ± 0.09 %ID/g, 7.02 ± 0.99 %ID/g, 8.87 ± 0.92 %ID/g, 
11.79 ± 2.15 %ID/g and 15.10 ± 1.40 %ID/g at 1, 24, 48, 72 and 96 h after injection, 
respectively. The tumor-to-heart, tumor-to-liver and tumor-to-muscle ratios were 3.66 
± 0.34, 5.36 ± 0.50 and 29.70 ± 2.76, respectively, at 96 h after injection. While for 125I-
mIgG, almost no MDA-MB-231 tumor uptake was observed at all time-points after 
injection. 
In the fifth chapter, we conducted radioimmunotherapy studies, 131I-aICAM1 can 
significantly inhibit the growth of MDA-MB-231 tumors. 
125I-aICAM1 is a new potent tracer to detect ICAM-1 expression in vivo using 
SPECT. The probe is expected to provide information on the molecular typing of breast 
cancer. The feasibility of SPECT imaging with 125I-aICAM1 for noninvasively TNBC 
identification and corresponding image-guided tumor radiotherapy with 131I-aICAM1 
will be demonstrated in the future. 
Keywords: Breast cancer; Radioiodination; SPECT; ICAM-1; Triple negative breast 
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第一章 前 言 
1.1 乳腺癌 
2017 年 2 月，世界卫生组织推出的《癌症早期诊断指南》显示每年有 880 万
人死于癌症。在世界范围内，癌症死亡人数占总死亡人数的近六分之一。报告显















国女性乳腺癌发病病例约 26.9 万例，死亡病例约 7.0 万例，分别占女性总发病和





























2) 及 Ki 67 是临床常用乳腺癌分子标志物，反映乳腺癌的不同分子病理特征。根
据这些受体表达与否或是表达量的不同，其治疗的策略，疾病的预后都有所差异。 
2000 年，Perou 等[9]最先对乳腺癌的基因表达进行研究，并提出了乳腺癌的
分子分型，并将乳腺癌分为 4 种亚型，管腔型，即 ER(+)PR(-)HER-2(-)；HER-2
高表达型，即 ER(-)PR(-)HER-2(+)；基底样型，即 ER(-)PR(-)HER-2(-)；正常乳
腺样型。 2003 年，Sorlie 等 [10] 将管腔型进一步分为 Luminal A 型，即




表 1.1 乳腺癌分子亚型及其特征 
Table 1.1 Breast cancer molecular classification and its characteristics 
















































然而，三阴性乳腺癌（triple negative breast cancer, TNBC）的生存率却仍没有提
高。TNBC 是一种特殊类型的乳腺癌，是免疫组织化学染色 ER、PR 和 HER-2 表
达均为阴性的乳腺癌，具有独特的生物学特性和临床病理特征。其许多生物学特
性和基底细胞样型乳腺癌相似，但两者之间存在某些基因表达谱和免疫表型上的
差异，因此亦不能完全等同[6]。TNBC 肿瘤侵袭能力强，由于 TNBC 的异质性及
缺乏内分泌及抗 HER-2 治疗的靶点，尚无针对性的标准治疗方案，化疗仍是
TNBC 患者的主要治疗手段。被确诊为 TNBC 的患者 2 年内疾病的复发风险远
远高于其他亚型的患者[11]，TNBC 的治疗面临着严峻的挑战。TNBC 占所有乳腺
癌亚型的 11％-20％[12, 13]，多发于 50 岁以下女性，严重危害女性健康，了解其成
像特征是非常重要的。 
调查 TNBC 乳腺 X 线摄影检查的研究发现在 TNBC 与 HER-2 阳性和 ER 阳
性的乳腺癌之间存在显著差异[14-18]。尽管与其他乳腺癌免疫表型相比，TNBC 诊
断尺寸较大，但仍有高达 18％的 TNBC 隐匿在初次乳腺 X 线摄影下[14-16]。在乳
腺 X 线摄影术中，TNBC 最常见的表现是肿块，有 20％-24％的病例（图 1A）有
清晰边界，49％-100％的病例没有钙化[14, 16, 18]。或者，TNBC 呈现局限性不对称
（9％-22％），或与肿块相关的钙化（15％）[15, 16]。在 TNBC 中伴有钙化的现象
（15%）明显低于 HER2 阳性（67％）和 ER 阳性（61％）乳腺癌（P <0.0001）
[14, 15]。 
TNBC 缺乏乳腺癌的典型可疑乳腺 X 线摄影特征：不规则的肿块形状，毛刺
样边缘和相关的可疑钙化（表 1）[19]。因此，单独的乳腺 X 线检查通常是初步诊
断评估的次优手段。此外，缺乏相关的钙化和相关的乳腺导管内原位癌（DCIS）
的低发生率[15, 16]表明 TNBC 绕过原位阶段的快速致癌作用。TNBC 的乳腺 X 线
摄影征象表明肿瘤生长迅速，直接进入浸润性阶段。因此，在筛查患者 TNBC 发
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